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ABSTRACT
Thromboembolic events are the most frequent complications and second leading cause of death among cancer 
patients. The most common forms include deep venous thrombosis of lower extremities and pulmonary embolism. 
The risk of thrombosis is correlated with underlying, patient’s clinical characteristic, functions of coagulation system 
as well as anticancer treatment. There is a well-established evidence for using of antithrombotic prophylaxis in 
cancer patients undergoing surgery and hospitalised due to different causes. There are some scores, based on 
laboratory and clinical factors, that facilitate qualification to the prophylaxis (e.g. Caprini score, Padua Prediction 
Score). The role of low-molecular-weight heparins (LMWH) in prophylaxis of thrombosis in cancer patients was 
established based on the results of many randomised clinical trials. Currently, the use this group of drugs — both 
in the treatment and in prophylaxis of venous thromboembolism (VTE) — is a part of standard of care. Nadroparin 
is one of the LMWHs with well-documented efficacy and safety in cancer patients. 
Key words: venous thromboembolism, cancer, nadroparin, thrombosis prophylaxis, thrombosis treatment, 
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Thromboembolic complications  
in cancer patients
Thromboembolic events (TE) are the most frequent 
complication and second leading cause of death in 
cancer patients [1, 2]. Diagnosis of cancer increases 
the risk of thrombosis by 4–6-fold and the prevalence 
is affected by cancer stage, (4–13-fold more prevalent 
in patients with metastatic disease as compared to lo-
cal cancer), type (approximately one third of pancre-
atic and lung cancer patients have thrombotic events 
vs. approximately 15% of patients with other types of 
cancer), and histology (incidence of thrombosis differs 
between different histologic types of lung cancer) [3]. 
Furthermore, the recurrence of TE events in cancer 
patients is 3 times more frequent than in non-cancer 
patients, and the risk of death due to thrombosis is as 
much as eight times higher [4]. In parallel, occurrence 
of thrombosis or embolism is an unfavourable prog-
nostic factor, and overall survival time is significantly 
shorter as compared to the patients without such com-
plications [1, 2].
In the nineteenth century Professor Armand Trous-
seau noticed that venous thromboembolism (VTE) is 
much more frequent in cancer patients. Currently, it 
is very well recognised that cancer development and 
coagulation disorders are inextricably interlinked. 
There are different causes of such disorders, including 
primarily procoagulant activity as well as cytokines, 
which are produced and released by cancer cells. They 
influence host monocytes/macrophages, endothelial 
cells, and platelets inducing prothrombotic activity. 
Tissue factor (TF) is the most important procoagulant 
in cancer patients. TF expression was documented in 
the majority of tumours, like breast, pancreatic, lung, 
gastric cancer, glioblastoma, and melanoma. Addition-
ally, it was proven that TF expression on the surface 
of cancer cells could be associated with a decrease in 
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overall survival (e.g. in breast cancer patients) or higher 
prevalence of metastatic disease (e.g. in colon cancer 
patients) [5]. 
The pathophysiology of thromboembolic complica-
tions is described by the still valid classical Virchow’s 
triad, that includes changes of blood flow, endothelial 
damage, and changes within blood components. Causes 
of blood flow impairment in cancer patients broadly vary, 
including patient’s immobilisation, external pressure of 
bulky mass on blood vessels, as well as during congestive 
heart failure resulting from cancer treatment-related 
cardiomyopathy. Hypoxia also affects blood flow, very 
often intensified by anaemia, being a consequence of 
either cancer itself or its treatment [6]. Of note, cor-
relation between haemostatic disturbances and cancer 
is mutual, as current clinical trial results show, because 
cancer-dependent activation of coagulation cascade 
influences cancer growth, tumour neo-angiogenesis, 
and formation of distant metastases [7, 8].
Different forms of thromboembolic 
episodes
The most frequent clinical pictures of VTE in 
cancer patients are deep venous thrombosis (DVT) of 
lower extremities and pulmonary embolism (PE). Ad-
ditionally, the most characteristic form of thrombosis 
in this group of patients is Trousseau’s syndrome, e.g. 
migratory thrombosis of superficial veins. Below are 
discussed some clinical forms of thromboembolic com-
plications, a detailed description of which is presented 
elsewhere [9].
Deep venous thrombosis (DVT) of lower 
extremities
Suspicion of DVT of lower extremities could be 
driven by some clinical symptoms from lower leg, like 
oedema, erythema (or bruising) of skin, and changes 
of skin warmth. Those signs and symptoms could be 
accompanied by pain of the lower leg or entire lower 
extremity. Diagnosis is based on compression ultrasound 
(US) examination, and more rarely on magnetic reso-
nance angiography (MRA) or phlebography.
Deep venous thrombosis (DVT) of upper 
extremities
Especially predisposed to this form of thrombosis are 
patients with mediastinal tumours or lymphomas with 
axillary lymph node involvement, patients after central 
venous access device implantation, and patients treated 
with intravenous chemotherapy. Clinical signs and symp-
toms of upper extremities DVT are mostly unspecific or 
are simply lacking. Extremity oedema, erythema and 
increased skin warmth, and pain are noticeable, which 
could also involve the shoulder, axillary region, lower 
jaw, neck or head, as well as collateral circulation on 
the chest, together with symptoms of Superior Vena 
Cava Syndrome (SVCS). Upper extremities DVT may 
be complicated by PE (8–35% of patients) and chronic 
venous insufficiency (20–50%) [9]. Similarly to lower 
extremities DVT, diagnosis is established based on 
Doppler US, MRA, or phlebography. 
Pulmonary embolism (PE)
The first clinical symptoms of PE are of sudden 
onset, most frequently as chest pain, intensifying dur-
ing cough or attempting a deep breath, and could be 
accompanied by dizziness and syncope. Sudden ventila-
tion impairment (dyspnoea) leads to suspicion of PE. 
Apart from computed tomography (CT) angiography 
diagnostic workout should include total blood count 
(TBC), APTT (activated partial thromboplastin time), 
INR (international normalised ratio), renal function, 
acid-base balance, and assessment of cardiac function 
and blood pressure (BP) monitoring. 
Migratory thrombosis of superficial veins 
(Trousseau’s syndrome)
Trousseau’s syndrome presents with recurrent 
thrombosis in different localisations observed in patients 
with predisposing factors. It could be placed in different 
superficial veins, most frequently of unusual localisation. 
Very typical is spontaneous resolution and resistance to 
standard management. Migratory superficial phlebitis is 
mostly observed in patients with pancreatic cancer and 
other gastrointestinal (GI) malignancies.
Hepatic veins thrombosis (Budd-Chiari syndrome)
Hepatic veins thrombosis (HVT) is most frequently 
seen in patients with myeloproliferative syndromes. The 
symptoms include the presence of ascites, hepatomegaly, 
and abdominal pain.
Thrombosis of portal, splenic, visceral, and renal 
veins
These changes are primarily observed in patients 
with myeloproliferative syndromes, and more rarely 
in patients with primary hepatic, renal, and suprarenal 
gland cancers. The most frequent symptoms of thrombo-
sis in these localisations are: splenomegaly, oesophageal 
varicose, abdominal pain, and ascites. Imaging evalu-
ation techniques include US, CT, MR, scintigraphy, 
and phlebography.
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Non-bacterial thrombotic endocarditis (NBTE)
This type of TE is the most commonly diagnosed 
in patients with mucus-producing GI adenocarcinoma 
and other cancers in higher stages. Usually, throm-
botic foci develop as the first within affected valves, 
both aortal and mitral. The most frequent symptom 
of NBTE is newly diagnosed heart murmur, but often 
the complication of NBTE is the only symptom of the 
disease, including embolism of arteries: cerebral, coro-
nary, splenic, renal, and extremities. Echocardiographic 
evaluation (ECHO) enables the appropriate diagnosis 
to be established. 
Thrombosis risk assessment and 
primary prophylaxis
The risk of development of VTE in cancer patients 
is connected with patient-related factors, cancer type, as 
well as therapeutic modalities. Patient-related — most 
frequent — VTE risk factors include: age, male gen-
der, black race, immobilisation, obesity, concomitant 
diseases, and previous thrombosis. Cancer-related im-
portant factors are: histology, clinical stage and primary 
location (the highest treatment of VTE is correlated with 
pancreatic, lung, ovarian, hepatic, and gastric cancer and 
some haematological malignancies) [10], pressure and 
damage of blood vessel by bulky mass, and production 
and release of pro-coagulation factors and cytokines by 
cancer cells (e.g. it was shown that high expression of 
tissue factor in cancer cells derived from totally resected 
tumours is connected with increased VTE risk during the 
postoperative period) [5]. The use of chemotherapy in 
anticancer treatment could increase the risk of VTE by 
six-fold [11]. The pathophysiology of this phenomenon 
is quite complicated, combining damage of endothelial 
cells, decreased level of natural coagulation inhibitors 
(C-protein, S-protein, antithrombin), and platelets ac-
tivation. The drugs used in systemic therapy in cancer 
patients, which are related to the highest VTE risk, 
include: thalidomide, angiogenesis inhibitors, hormones 
(tamoxifen in particular), and some agents  that are 
used for supportive care, such as granulocyte-colony 
stimulating factors (G-CFRs), erythropoiesis stimulat-
ing factors, and megestrol acetate [12–14]. Additionally, 
catheterisation of central veins could also be related to 
increased risk of thromboembolic complications [15]. 
Surgical procedures significantly increase VTE risk. 
Especially high risk applies to patients with positive 
VTE history, those having undergone general anaes-
thesia longer than two hours, and patients who have 
stayed in bed for longer than two days after operation 
[1]. Furthermore, radiotherapy could also increase the 
risk of thrombosis [16].
Currently the efficacy of antithrombotic prophylaxis 
in surgically treated cancer patients and in those hos-
pitalised due to surgical treatment or medical causes 
is quite well documented. In these groups of patients 
antithrombotic prophylaxis is recommended by oncology 
societies and experts. Despite comparable efficacy of 
unfractionated heparin (UFH), low-molecular-weight 
heparins (LMWH), fondaparinux, and warfarin in 
VTE prophylaxis, most clinical trials to date have been 
dedicated to the analysis of LMWH activity and safety. 
This results from the many benefits of this class of 
drugs, mainly as directly compared to UFH: possibil-
ity of once daily administration of a therapeutic dose, 
favourable pharmacokinetic (PK) profile, and lower risk 
of heparin-induced thrombocytopaenia. 
Prophylaxis in patients after surgical 
cancer treatment
Surgical treatment increases by 3–5-fold the VTE 
risk in cancer patients undergoing surgery due to cancer 
as compared to patients with other diseases, who have 
undergone operations. The recommendations in this 
group of patients assume initiation of VTE prophylaxis 
with LMWH before operation, and then its continua-
tion once daily in doses according to the labels [17–19].
Antithrombotic prophylaxis should be used in all 
patients after surgery with high risk of VTE, provided 
no contraindications exist (mainly connected to high 
risk of bleeding complications). However, in the group 
of VTE intermediate-risk patients, the use of antithrom-
botic prophylaxis is suggested. Evaluation of threatening 
levels of VTE occurrence in patients during operation 
could be performed using one of the available scores, 
e.g. the Caprini score (Tab. 1), whereas the duration 
of prophylaxis depends on the type of resection. Ac-
cording to the European Society of Medical Oncology 
(ESMO) [and the American Society of Clinical Oncol-
ogy (ASCO), American College of Clinical Pharmacy 
(ACCP), etc.] recommendations, in case of laparoscopic 
procedures, laparotomy, and thoracoscopy lasting longer 
than 30 minutes — LMWH should be used for at least 
10 days after operation. However, in cancer patients who 
have undergone abdominal and pelvis minor resections 
prophylaxis using LMWH should be continued for up 
to one month after operation [18].
There is a great deal of evidence supporting this 
approach. Whilst they are different for particular LM-
WHs, the use of nadroparin is well documented. One 
of the first clinical trials with a separated subgroup of 
cancer patients was the prospective, randomised study 
led by Encke et al. [20]. The researchers compared 
the efficacy of nadroparin with UFH in prophylaxis 
of DVT in patients undergoing abdominal surgery. 
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Table 1. Caprini DVT risk assessment score [32]
1 point 2 points 3 points 5 points
Age 41–60 years Age 61–74 years Age ≥ 75 years Experienced a stroke 
(< 1 month)
Minor surgery Arthroscopic surgery History of deep vein thrombosis 
or pulmonary embolism
Planned (elective) 
alloplastic surgery of 
joint
BMI > 25 kg/m2 Major open surgery (> 45 min) Family history of history of deep 
vein thrombosis or pulmonary 
embolism
Pelvis, thigh, or shin 
bone fracture
Swollen legs (peripheral oedema) Laparoscopic surgery (> 45 min) V Leiden factor Severe spinal cord 
injury (< 1 month)
Varicose veins Malignant disease G20210A prothrombin gene 
mutation
Pregnancy or post-delivery period Confined to bed (> 72 hours) Lupus anticoagulant
History of unexplained or 
repeated stillborn
Non-removable plaster cast that 
has kept from moving
Anticardiolipin antibodies
Oral contraception or hormonal 
replacement therapy
Central venous access Anti-b2-GPI antibodies
Sepsis (< 1 month) Elevated serum level of 
homocysteine
Serious lung disease, including 
pneumonia (< 1 month)
Heparin inducted 
thrombocytopaenia (HIT)
Lung dysfunction Other congenital or acquired 
thrombophilia
Acute myocardial infarction
Exacerbation or diagnosis of 
heart failure (< 1 month)
History of inflammatory bowel 
disease
Conservative treatment,  
on bed rest
0 point — very low risk; 1–2 points — low risk; 3–4 points — intermediate risk; ≥ 5 points — high risk
The prevalence of thrombosis in 694 cancer patients 
(among a total of 1896 included patients) was lower in 
the group receiving nadroparin as compared to UFH, 
and there was no difference in the treatment-related 
bleeding complications [20]. In turn, in another clinical 
trial Pezzuoli et al. [21] compared use of nadroparin 
with placebo in antithrombotic prophylaxis in a group of 
4498 surgically treated patients (among which 1507 were 
operated due to cancer). The risk of death was lower in 
the group of patients treated with nadroparin, according 
to general mortality as well as deaths specifically related 
to thromboembolic complications [21]. Simonneau et al. 
[22] performed a clinical trial evaluating the influence of 
antithrombotic prophylaxis on the frequency of throm-
boembolic complications in cancer patients upon surgi-
cal treatment. The efficacy and safety of nadroparin in 
the dose of 0.3 mL (2850 IU) were analysed comparing 
to enoxaparin in the dose of 0.4 mL (40 mg) in throm-
bosis prevention in a group of nearly 1300 patients with 
colon cancer undergoing surgical treatment with cura-
tive intent. Interestingly, the use of nadroparin in this 
study was correlated with a significantly lower number 
of bleeding complications. Furthermore, symptomatic 
VTE was rarer in the group of patients receiving nadro-
parin [22]. Meta-analysis of 51 clinical trials comparing 
LMWH (including five with nadroparin) and UFH in 
operated patients indicated that LMWH as a class are at 
least as effective as UFH in VTE prophylaxis. However, 
nadroparin was the only LMWH with higher efficacy 
in prophylaxis of asymptomatic and overt VTE than 
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UFH [23]. The dose of nadroparin in this indication was 
precisely established in a study led by Azorin et al. [24], 
in which surgically treated lung cancer patients were 
randomly assigned to one of two therapeutic groups. In 
the first arm antithrombotic prophylaxis was used with 
nadroparin in the stable dose of 0.3 mL (2850 IU), whilst 
in the second arm the dose was adjusted to body weight [in 
patients under 70 kg — 0.4 mL (3800 IU), and in patients 
over 70 kg — 0.6 mL (5700 IU)]. Based on the results the 
0.3 mL dose of nadroparin is characterised by the best 
benefit:risk ratio according to the complications risk; 
therefore, this is the recommended dose in antithrombotic 
prophylaxis in surgically treated cancer patients [24].
Prophylaxis in cancer patients with 
systemic treatment
According to the ESMO (and the ASCO and ACCP) 
recommendations in cancer patients hospitalised due to 
medical causes, especially from emergencies, as well as 
in patients in general bad health status, staying in bed for 
the majority of time, primary VTE prophylaxis should 
be used. To asses VTE risk in hospitalised patients, use 
of the Padua Prediction Score could be helpful (Tab. 2) 
[25]. Of note, the majority of cancer patients assessed 
based on this score would be classified to a high-risk 
group, which should be a premise for the introduction 
of prophylaxis in the majority of patients. Additionally, 
patient immobilisation supports this approach, and 
some systemically treated patients significantly reduce 
physical activity due to weakness after chemotherapy, 
cancer fatigue syndrome, nausea, etc. It should also be 
remembered that the International Society of Thrombo-
sis and Haemostasis (ISTH) does not recommend VTE 
prophylaxis in patients hospitalised for a short period 
just for chemotherapy infusion [25, 26]. 
The use of antithrombotic prophylaxis in cancer 
patients with systemic therapy depends on many fac-
tors (among them — histology, stage, type, and aim 
of treatment). Routine prophylaxis in patients during 
palliative chemotherapy in the outpatient setting is not 
recommended. It could be considered in some patients 
with high thrombosis risk, e.g. in patients with pancre-
atic or non-small cell lung cancer. To assess the risk of 
thromboembolic complications in this group of patients 
the validated Khorana model could be used, including 
clinical and laboratory variables, which is presented 
in Table 3 [27]. The grading expressed in the number 
of points in this model reflects the probability of VTE 
occurrence. This model was supplemented by Austrian 
researchers with two additional laboratory parameters: 
D-dimer concentration and P-selectin concentration, 
which significantly increased sensitivity and specificity 
of this scale [28].
A clinical study made by Klerk et al. [29] provided 
some new data regarding the usefulness of nadroparin 
in cancer patients with conservative treatment. This 
study assessed the influence of nadroparin on overall 
survival in systematically (but not surgically) treated 
cancer patients. Nadroparin was used in the group of 
148 patients for a total of six weeks and compared with 
a control group of 154 patients receiving placebo. Mor-
tality dropped at 12 and 24 months by 12% and 10%, 
respectively, and median of overall survival was also 
increased by approximately 1.5 months (6.6 vs. 8 months, 
respectively). The effects of nadroparin use were more 
enhanced in patients with life expectancy of more than 
six months (15.4 vs. 9.4 months). However, there were 
no differences regarding others bleeding rates [29]. 
Table 2. Venous thromboembolism (VTE) risk assessment model in hospitalised patients (Padua Prediction Score)
Active malignant neoplasm (patients with metastatic regional lymph nodes or distant metastases receiving 
chemotherapy or radiotherapy within last 6 months
3 points
History of VTE (despite superficial vein thrombosis) 3 points
Immobilisation (expected need of staying in bed [with possibility of bath/toilet use] due to patient’s incapacity or 
physician recommendation for ≥ 3 days)
3 points
Diagnosis of thrombophilia (antithrombin deficiency, protein C or S deficiency, V Leiden factor, G20210A prothrombin 
gene mutation, or antiphospholipid syndrome)
3 points
Recent (≤ 1 month) trauma or surgical procedure 2 points
Age ≥ 70 years 1 point
Heart failure or respiratory failure 1 point
Recent myocardial infarction or ischemic stroke 1 point
Severe infection or rheumatologic disease 1 point
Obesity (BMI ≥ 30 kg/m2) 1 point
Hormonal treatment 1 point
Sum of ≥ 4 points — high risk of venous thromboembolism (VTE); sum of < 4 points — low risk of VTE
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Table 3. Risk assessment score of VTE occurrence in cancer patients treated with chemotherapy in an outpatient setting
Parameters assessed:
— primary site of cancer (stomach, pancreas, brain — 2 points; lung, lymphoma, reproductive system, bladder, testicle, kidney — 1 point)
— PLT ≥ 350 × 109/L — 1 point
— haemoglobin concentration < 100 g/L and/or use of EPO — 1 point
— LEU > 11 × 109/L — 1 point
— BMI ≥ 35 kg/m2 — 1 point
Low-risk category (0 risk factors) — risk of thromboembolic complications < 1%
Intermediate-risk category (1–2) — risk of thromboembolic complications app. 2%
High-risk category (≥ 3) — risk of thromboembolic complications app. 7%
Table 4. Clinical trials assessing nadroparin at the dose of 2850 IU 1 × daily in the prevention of thromboembolic 
complications in cancer patients (adapted from [43])
Study Study population % of cancer 
patients
Comparator
Azorin et al. Operated on due to lung cancer (n = 150) 100% Nadroparin at the dose 
of 3.800 IU in patients 
weight ≤ 70 kg or at the 
dose of 5.700 IU in patients 
weight > 70 kg
Boncinelli et al. Underwent urological surgery (n = 50) 100% UFH 5000 U 3/day
Bounameaux et al. Underwent abdominal surgery (n = 194) 47.4% Dalteparin 2500 IU 1/day
European Fraxiparin 
Study
Underwent abdominal surgery (n = 1.896) 36.6% UFH 5000 U 3/day
Harenberg et al. Bedridden patients (n = 1 590) 7.5% UFH 5000 U 3/day
Marassi et al. Underwent abdominal surgery (n = 61) 100% No treatment
Mismetti et al. Patients with malignant neoplasms and central venous 
access (n = 59)
100% Warfarin 1 mg 1/day
Niers et al. Patients with haematological malignancies and central 
venous access (n = 113)
100% Placebo
Nurmohamed et al.* Underwent neurological surgery (n = 485) 82.5% Compression stockings
Pezzuoli et al. Underwent surgery (n = 4 498) 33.5% Placebo
Simonneau et al. Operated on due to colorectal cancer(n = 1 288) 100% Enoxaparin 40 mg 1/day
Weber et al.** Cancer patients with palliative care (n = 20) 100% No treatment
*Despite nadroparin compression stockings were used as well; **in patients weighted over 70 kg nadroparin was used at the dose of 3800 IU; UFH — un-
fractionated heparin
The PROTECHT study [30] also provided very 
interesting data. This placebo-controlled trial assessed 
the prophylactic effect of nadroparin 0.4 mL (3800 IU) 
on thromboembolic complications in cancer patients 
exposed to chemotherapy. A total of 1166 patients were 
included — they were exposed to palliative chemotherapy 
due to lung, GI, breast, ovarian, or head and neck cancer. 
The PROTECHT study indicated that in this group of 
patients prophylactically used nadroparin decreased the 
prevalence of thromboembolic episodes (2% vs. 3.9%); 
additionnally there was no increase in bleeding rate [30]. 
Furthermore, the results obtained in this study were 
stratified by VTE risk according to the Khorana model 
[31]. This analysis showed that introduction of primary 
prophylaxis with nadroparin in the group of VTE high-risk 
patients gives a decrease in the number of thromboem-
bolic complications by 62%. It is important to note that 
appropriate patient selection to nadroparin prophylaxis 
based on Khorana score allows limitation of the number 
of needed-to-treat (NNT) patients from 50 to 15 [31].
The presence of a central catheter in central veins 
or venous access port in cancer patient can be of con-
cern in terms of indications to primary antithrombotic 
prophylaxis. Different types of catheters, ports, and 
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Table 5. Studies assessing nadroparin in the treatment of thromboembolic complications in cancer patients (adapted 
from [43])
Study Thromboembolic event 
Number of patients included
% of patients  
with cancer
Nadroparin dose Comparator
Charbonnier 
et al.
Proximal deep vein thrombosis
n = 651
14% Double dose estimated per 
body weight 1/day
Nadroparin at the dose 
estimated per body weight 
2/day
Koopman et al. Proximal deep vein thrombosis 
(outpatient treatment)
n = 400
17.5% Due dose estimated per 
body weight 2/day
UFH — dose adjusted 
according to APTT
Lopaciuk et al. Proximal deep vein thrombosis 
(extension therapy)
n = 193
6.2% Dose estimated per body 
weight 1/day
Acenocoumarol — dose 
adjusted according to INR 
for 6 months
Lopez-Beret et al. Proximal deep vein thrombosis 
(extension therapy)
n = 158
22.2% Dose estimated per 
body weight 2/day for 
3 months ± dose estimated 
per body weight 1/day
Acenocoumarol — dose 
adjusted according to INR 
for 3–6 months
Prandoni et al. Proximal deep vein thrombosis
n = 170
19.4% Dose estimated per 
body weight 2/day for 
3 subsequent months 
Intravenous UFH — dose 
adjusted according to APTT
Prandoni et al. Venous thromboembolism
n = 720
21.7% Dose estimated per body 
weight 2/day
Subcutaneous UFH — dose 
adjusted according to APTT
APTT — activated partial thromboplastin time; UFH — unfractionated heparin; INR — international normalized ratio
Table 6. Studies assessing influence of nadroparin on OS and TTP in cancer patients in comparison to placebo or no 
treatment (adapted from [43])
Study Type of cancer 
Number of patients included
Nadroparin dose
Icli et al.*, ## Pancreatic cancer
n = 69
0.3 mL (2850 IU) 1/day for 8 days every 3 weeks (average 6 cycles)
INPACT*, ## Pancreatic, lung or prostate cancer
n = 500
Therapeutic doses for 2 weeks, followed by 1/2 dose for 4 weeks
After 4 weeks break — 2-weeks of therapeutic doses, 6 cycles
Klerk et al.* ,# Various
n = 302
0.4 mL (3800 IU) < 50 kg
0.6 mL (5700 IU) 50–70 kg
0.8 mL (7600 IU) > 70 kg
2/day for 2 weeks, followed by 1/day for 4 weeks
NVALT-8b**, ## Non-small-cell lung cancer after surgery 
with high risk of recurrence  
n = 600
Starting 4–6 weeks after surgery: therapeutic dose for 2 weeks, 
followed by half of therapeutic dose for 14 weeks
*Assessed OS; **assessed TTP 
Comparator: #placebo, ##no treatment
central vein devices are more frequently used during 
systemic treatment. Despite the fact that such equipment 
increases the patient’s predisposition to thrombosis 
in upper extremity veins, routine VTE prophylaxis is 
not recommended [32]. The management should be 
individualised, depending on additional VTE risk fac-
tors. Interestingly, the prevalence of VTE in connected 
with the localisation of the catheter and is lowest when 
it is placed in the right jugular vein.
Initial, long-term, and chronic 
treatment of VTE in cancer patients
Treatment of VTE in cancer patients significantly 
differs from the management in patients without malig-
nancy. Primarily it should be considered that thrombosis 
prevalence in cancer patients is 2–5-fold higher, and 
additionally bleeding complications are 2–6-fold more 
frequent [4]. Use of LMWH is a method of choice in 
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cancer patients with normal renal function during the 
initial phase of thrombosis treatment as well as in pro-
longed treatment. This approach is recommended by 
various scientific societies as well as by experts. There 
were no differences according VTE recurrence rate 
and bleeding rate in analysis comparing the efficacy 
and safety of UFH and LMWH during initial treatment 
of VTE episodes; however, a trend was observed in 
favour of LMWH according to a decreased mortality 
[33]. Additionally, LMWH was compared with vitamin 
K antagonists (VKA) in prolonged treatment and it was 
revealed that relapse and bleeding rates were lower in 
patients treated with LMWH, whilst there was no differ-
ence in mortality rate between the groups [34–36]. The 
possibility of using oral anticoagulants in cancer patients 
also is limited by numerous drug-drug and drug-food 
interactions in this group of agents. Therapy with VKAs 
requires invasive monitoring of INR levels (as a standard 
it should be within the range 2.0–3.0). However, in can-
cer patients frequent and significant INR fluctuations 
are observed during therapy with VKAs. As a result, 
these patients may experience increased risk of bleeding 
complications (INR over 3.0 — excessive anticoagula-
tion), but increased thrombosis risk may exist (INR 
below 2.0 — insufficient anticoagulation). 
Prandoni et al. [37] compared use of nadroparin 
and UNF according to aPTT level in the treatment of 
phlebography-confirmed DVT. Risk of death in cancer 
patients, comprising nearly 20% of all eligible patients, 
was significantly reduced at six months (44% vs. 7%). Of 
note, in patients without cancer such differences were 
not observed [37]. Results of meta-analysis of 13 clini-
cal trials comparing LMWH with UFH used in VTE 
treatment (Dolovich et al. [38]) confirmed the efficacy 
of LMWH as a class and additionally indicated the dif-
ferences in safety profile between LMWH and UFH 
in favour of the former, and also between particular 
LMWHs — e.g. major bleeds were the most uncommon 
in nadroparin-treated patients [38]. 
According to ESMO recommendations, the use of 
LMWH administered for four weeks in full therapeutic 
dose and thereafter in a maintenance dose amounting to 
approximately 75–90% of starting dose is a standard of 
care in the treatment of TE in cancer patients [39], but 
the ASCO and ACCP recommend prolonged treatment 
without indicating a specific dose of drug. 
The first three months is known as active VTE treat-
ment, and its follow-up, aimed at reducing the risk of late 
thrombosis recurrence, is defined as prolonged therapy. 
The duration of this treatment phase is individualised, 
but it should last the entire time during which the risk 
factors of thrombosis recurrence sustain. It could lead 
in practice to the need for continuous treatment until 
cancer cure, and in uncommon cases even until terminal 
phase of disease. It should be also highlighted that not 
all LMWHs bring benefits in this indication. A study 
evaluating the efficacy of enoxaparin in maintenance 
treatment did not indicate any lowering of thrombosis 
recurrence risk in cancer patients [40]. 
Lopez-Beret et al. [41] compared nadroparin with 
oral anticoagulants (acenocoumarol administered based 
on INR monitoring) in prolonged VTE treatment 
(cancer patients comprised 22% of included patients). 
There were no differences according to the prevalence 
of thromboembolism episodes, bleeding complications, 
and deaths. However, an increased rate of recanalisation 
of blood vessels with thrombosis was noticed, as well as 
a lower number of late valvular insufficiencies in pen-
etrating veins in patients treated with nadroparin [41]. 
The requirement of daily subcutaneous injections 
with concomitant pain could discourage patients from 
being compliant during treatment with heparins. Billon 
et al. [42] assessed in healthy volunteers local soreness 
connected to subcutaneous injections of enoxaparin 
and nadroparin. Self-assessed soreness was significantly 
lower in individuals taking nadroparin [42]. 
It should also be remembered that LMWHs are 
excreted by kidneys — in patients with severe renal 
impairment (estimated creatinine clearance below 
30 mL/minute) the half-life of LMWH is prolonged and 
dose verification (based on anti-Xa activity) or the use 
of UFH is required. 
Summary
Thromboembolic complications significantly wors-
ens the prognosis in cancer patients. The treatment of 
VTE in this group of patients is uncommonly challeng-
ing. Antithrombotic prophylaxis is currently being used 
in a significant proportion of cancer patients, and its in-
troduction depends among others on treatment modality 
(surgical vs. conservative). LMWHs remain a group 
of drugs recommended for use in VTE prophylaxis in 
cancer patients as well as for treatment of thrombotic 
episodes. Nadroparin has proven efficacy and a favour-
able safety profile in cancer patients (Tabs. 4–6) [43]. 
It is included in the recommendations of different 
scientific societies as the only LMWH recommended 
for prophylaxis as well as treatment of thromboembolic 
complications in cancer patients.
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